This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
IDRA-21
A potent benzothiadiazine-derived ampakine that positively modulates AMPA receptors, producing long-lasting cognitive enhancement effects lasting up to 48 hours from a single dose.
Benefits
What is IDRA-21?
IDRA-21 (7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide) is a benzothiadiazine derivative classified as a positive allosteric modulator of AMPA receptors, placing it in the ampakine family of cognitive enhancers. Developed as a research compound for studying glutamatergic neurotransmission, IDRA-21 has attracted significant attention in the nootropic community due to its remarkable potency and duration of action. Preclinical studies have demonstrated that IDRA-21 is approximately 10-fold more potent than aniracetam at reducing AMPA receptor desensitisation, and a single administration can produce measurable cognitive enhancement lasting 24-48 hours in animal models. Research by Thompson et al. (1995) published in Neuropharmacology showed that IDRA-21 significantly improved performance in delayed matching-to-sample tasks in primates at doses as low as 0.3 mg/kg.
The mechanism of IDRA-21 centres on its ability to bind to the cyclothiazide site on AMPA receptors, slowing the rate of receptor desensitisation and thereby prolonging excitatory postsynaptic currents. This results in enhanced synaptic transmission and facilitation of long-term potentiation (LTP), the cellular substrate of learning and memory. Studies by Zivkovic et al. (1995) demonstrated that IDRA-21 reversed cognitive deficits induced by alprazolam (a benzodiazepine) and scopolamine (an anticholinergic) in rodent models, suggesting therapeutic potential for drug-induced and age-related cognitive impairment. Despite these promising preclinical findings, IDRA-21 has never entered formal clinical trials in humans and remains an unscheduled research chemical. Its use in the nootropic community is based primarily on extrapolation from animal data and anecdotal reports.
- AMPA receptor positive allosteric modulation: Binds to the cyclothiazide binding site on AMPA receptors, reducing the rate and extent of receptor desensitisation, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic transmission
- Long-term potentiation enhancement: Facilitates LTP induction in hippocampal and cortical neurons by amplifying AMPA receptor-mediated depolarisation, which enhances NMDA receptor activation through removal of the magnesium block
- BDNF upregulation: Enhanced AMPA receptor signalling triggers activity-dependent release of brain-derived neurotrophic factor (BDNF), which supports synaptic plasticity, neuronal survival, and dendritic growth
- Extended duration of action: The unusually long-lasting effects (24-48 hours) are thought to result from persistent changes in AMPA receptor conformation and downstream signalling cascades rather than from prolonged receptor occupancy
- Reversal of pharmacological cognitive impairment: Effectively counteracts cognitive deficits induced by benzodiazepines, anticholinergics, and other CNS depressants through restoration of glutamatergic excitatory tone
- Preclinical effective doses: Animal studies used doses of 0.3-10 mg/kg, with cognitive enhancement observed at the lower end of this range in primate studies
- Anecdotal human dosing: Self-experimenters in the nootropic community have reported using 5-15 mg per dose, though no human clinical trials have established safe or effective dosing
- Frequency of dosing: Given the 24-48 hour duration of effects observed in animal studies, many users report dosing only every 2-3 days rather than daily
- Route of administration: Typically taken orally in capsule or powder form; sublingual administration has been reported anecdotally to increase onset speed
- Important caveat: All human dosing information is extrapolated from animal research or anecdotal reports; no controlled human pharmacokinetic or dose-finding studies have been conducted
- No human safety data: IDRA-21 has never undergone formal human clinical trials, meaning its safety profile in humans is entirely unknown and based only on animal toxicology and anecdotal reports
- Excitotoxicity risk: As a potent enhancer of glutamatergic transmission, excessive doses could theoretically promote excitotoxic neuronal damage through sustained calcium influx via AMPA and NMDA receptors
- Seizure threshold concerns: Enhanced excitatory neurotransmission carries inherent risk of lowering seizure threshold, particularly in individuals with epilepsy or other seizure disorders
- Unknown long-term effects: Chronic use effects on AMPA receptor density, desensitisation kinetics, and overall glutamatergic homeostasis have not been studied
- Purity and contamination risks: Available only as a research chemical without pharmaceutical-grade manufacturing standards; users face risks of contamination, mislabelling, and inconsistent potency
Natural Sources & Forms
- Thompson et al. (1995): "IDRA-21, a positive modulator of the AMPA receptor, improves delayed matching performance in rhesus monkeys" published in Neuropharmacology, demonstrating cognitive enhancement in primates
- Zivkovic et al. (1995): Research demonstrating IDRA-21's ability to reverse benzodiazepine- and scopolamine-induced cognitive deficits in rodent models of learning and memory
- Arai and Bhatt (2007): "Ampakines" chapter in Bentham Science comprehensive review covering IDRA-21 and related AMPA receptor modulators as cognitive enhancers
- Lynch (2006): "Glutamate-based therapeutic approaches: ampakines" in Current Opinion in Pharmacology, reviewing the therapeutic potential of AMPA receptor modulators including IDRA-21
- Bhatt et al. (2009): Review of ampakine mechanisms and their potential for treating cognitive dysfunction, contextualising IDRA-21 within the broader class of AMPA modulators
Frequently Asked Questions
A potent benzothiadiazine-derived ampakine that positively modulates AMPA receptors, producing long-lasting cognitive enhancement effects lasting up to 48 hours from a single dose.
The key benefits of IDRA-21 include: Cognitive Enhancement, Creativity, Focus, Memory, Motivation.
AMPA receptor positive allosteric modulation: Binds to the cyclothiazide binding site on AMPA receptors, reducing the rate and extent of receptor desensitisation, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic transmission Long-term potentiation enhancement: Facilitates LTP induction in hippocampal and cortical neurons by amplifying AMPA receptor-mediated depolarisation, which enhances NMDA receptor activation through removal of the magnesium block BDNF upregulation: Enhanced AMPA receptor signalling triggers activity-dependent release of brain-derived neurotrophic factor (BDNF), which supports synaptic plasticity, neuronal survival, and dendritic growth Extended duration of action: The unusually long-lasting effects (24-48 hours) are thought to result from persistent changes in AMPA receptor conformation and downstream signalling cascades rather than from prolonged receptor occupancy Reversal of pharmacological cognitive impairment: Effectively counteracts cognitive deficits induced by benzodiazepines, anticholinergics, and other CNS depressants through restoration of glutamatergic excitatory tone
Preclinical effective doses: Animal studies used doses of 0.3-10 mg/kg, with cognitive enhancement observed at the lower end of this range in primate studies Anecdotal human dosing: Self-experimenters in the nootropic community have reported using 5-15 mg per dose, though no human clinical trials have established safe or effective dosing Frequency of dosing: Given the 24-48 hour duration of effects observed in animal studies, many users report dosing only every 2-3 days rather than daily Route of administration: Typically taken orally in capsule or powder form; sublingual administration has been reported anecdotally to increase onset speed Important caveat: All human dosing information is extrapolated from animal research or anecdotal reports; no controlled human pharmacokinetic or dose-finding studies have been conducted
No human safety data: IDRA-21 has never undergone formal human clinical trials, meaning its safety profile in humans is entirely unknown and based only on animal toxicology and anecdotal reports Excitotoxicity risk: As a potent enhancer of glutamatergic transmission, excessive doses could theoretically promote excitotoxic neuronal damage through sustained calcium influx via AMPA and NMDA receptors Seizure threshold concerns: Enhanced excitatory neurotransmission carries inherent risk of lowering seizure threshold, particularly in individuals with epilepsy or other seizure disorders Unknown long-term effects: Chronic use effects on AMPA receptor density, desensitisation kinetics, and overall glutamatergic homeostasis have not been studied Purity and contamination risks: Available only as a research chemical without pharmaceutical-grade manufacturing standards; users face risks of contamination, mislabelling, and inconsistent potency
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!